In a parallel development, J&J and Legend Biotech are gearing up for an FDA meeting in the United States to discuss the expansion of Carvytki into earlier lines of treatment. Legend Biotech CEO, Ying Huang, anticipates that the meeting will predominantly scrutinize overall survival data, despite ongoing concerns about safety associated with CAR-T therapy, particularly the risk of secondary T-cell cancers.
This focus on overall survival underscores the FDA’s recent emphasis on using it as a composite metric for both efficacy and safety evaluation. While Carvytki has demonstrated promising survival benefits, concerns linger regarding potential toxicities, prompting thorough deliberation during regulatory reviews.
Meanwhile, Bristol Myers Squibb (BMS) faces challenges with their CAR-T therapy, Abecma, which failed to exhibit a significant extension in overall survival compared to standard treatments. The FDA remains cautious about negative trends in overall survival, even if attributed to patient crossover in clinical trials.
J&J and Legend remain optimistic about Carvytki’s potential, concurrently addressing manufacturing challenges to ensure product quality and consistency. However, ongoing safety and efficacy concerns underscore the critical need for comprehensive evaluation and discussion in upcoming regulatory proceedings on both sides of the Atlantic.
https://www.fiercepharma.com/pharma/legend-ceo-offers-preview-high-profile-fda-adcomm-jj-partnered-carvykti
https://www.biospace.com/article/eu-regulators-back-j-and-j-legend-s-carvykti-for-second-line-multiple-myeloma-ahead-of-adcomm/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Preclinical Studies Highlight Novel Gene Therapy for IgA Nephropathy Treatment
San Diego, CA – October 28, 2024 At the recent ASN Kidney Week 2024 (October 23–27), researchers presented promising preclinical data on PS-002, an innovative gene therapy aimed at treating IgA nephropathy (IgAN), an autoimmune kidney disease. The therapy, developed...
[2024/10/25] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Lipin1 Inhibition Enhances Axon Regeneration: A Potential Therapeutic Approach for Spinal Cord Injury
Traumatic injuries to the central nervous system (CNS) often result in permanent functional deficits due to the limited capacity of CNS neurons to regenerate. Although advancements in spinal cord injury (SCI) research have been made, achieving substantial nerve fiber...
CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and unpredictable swelling attacks caused by the disease hereditary...
Related Services
Plasmids GMP Services
AAV GMP Services
